EPZ5676: Potent and Selective DOT1L Inhibitor for MLL-Rearranged Leukemia Research

Executive Summary: EPZ5676 is a nanomolar-potency, SAM-competitive inhibitor of DOT1L, an enzyme critical to H3K79 methylation and MLL-rearranged leukemia biology (APExBIO). It exhibits an IC50 of 0.8 nM and Ki of 80 pM, with >37,000-fold selectivity against other methyltransferases (Anichini et al. 2022). In vivo, EPZ5676 induces complete regression of MV4-11 xenograft tumors at 35–70 mg/kg/day IV dosing, without significant toxicity. The compound is key in biochemical and cell-based assays, enabling precise inhibition of H3K79 methylation and robust antiproliferative profiling. Proper workflow integration and storage are essential to maintain activity and reproducibility.

Biological Rationale

DOT1L (Disruptor of Telomeric silencing 1-Like) is the only known histone methyltransferase that catalyzes methylation of lysine 79 on histone H3 (H3K79). H3K79 methylation regulates gene expression, cell cycle, and DNA repair (Anichini et al. 2022). Aberrant H3K79 methylation is implicated in MLL (Mixed-Lineage Leukemia) fusion-driven leukemias, where DOT1L activity is essential for the maintenance of leukemogenic gene expression programs. Inhibiting DOT1L disrupts this aberrant methylation, downregulates MLL fusion target genes, and impairs leukemic cell survival. EPZ5676, a highly selective DOT1L inhibitor, enables mechanistic interrogation and therapeutic exploration of these pathways. Its selectivity profile ensures minimal interference with other histone or protein methyltransferases, making it an ideal research reagent for dissecting epigenetic regulation in cancer (see related analysis).

Mechanism of Action of DOT1L inhibitor EPZ-5676

EPZ5676 operates as a competitive inhibitor targeting the S-adenosyl methionine (SAM) binding pocket of DOT1L (APExBIO). By occupying this site, EPZ5676 induces conformational changes in DOT1L, creating a hydrophobic pocket that extends beyond the amino acid portion of SAM. This unique interaction underlies its high potency (IC50 = 0.8 nM, Ki = 80 pM) and selectivity (>37,000-fold over other methyltransferases such as CARM1, EHMT1/2, EZH1/2, PRMTs, SETD7, SMYD2/3, and WHSC1/1L1). In MLL-rearranged leukemia models, EPZ5676 rapidly abrogates H3K79 methylation, leading to downregulation of leukemogenic gene networks and potent cytotoxicity in acute leukemia cell lines (IC50 = 3.5 nM in MV4-11 cells after 4–7 days). The selectivity profile of EPZ5676 minimizes off-target epigenetic effects, supporting its utility as a precision tool in epigenetic research and drug discovery (extended mechanistic review).

Evidence & Benchmarks

• EPZ5676 demonstrates an in vitro DOT1L inhibition IC50 of 0.8 nM at 25°C in biochemical assays (Anichini et al. 2022).
• Ki value for DOT1L inhibition is 80 pM, indicating high affinity under physiological buffer conditions (APExBIO product documentation).
• EPZ5676 shows >37,000-fold selectivity over other methyltransferases in panel assays at 10 μM substrate concentration (Anichini et al. 2022).
• MV4-11 leukemia cells exhibit antiproliferative IC50 of 3.5 nM after 4–7 days of exposure to EPZ5676 (APExBIO).
• In vivo, nude rats with MV4-11 xenografts receiving 35–70 mg/kg/day IV EPZ5676 for 21 days show complete tumor regression without significant toxicity or weight loss (Anichini et al. 2022).
• EPZ5676 is insoluble in water but dissolves at ≥28.15 mg/mL in DMSO and ≥50.3 mg/mL in ethanol with ultrasonic assistance at ambient temperature (APExBIO).
• Stock solutions are stable for several months at ≤ -20°C, but long-term storage of solutions at room temperature is not recommended (APExBIO).

Applications, Limits & Misconceptions

EPZ5676 is primarily used in biochemical DOT1L inhibition assays and cell-based studies of MLL-rearranged leukemias. Its nanomolar potency and selectivity enable researchers to specifically probe H3K79 methylation and downstream gene regulation. Applications extend to studying epigenetic regulation in additional cancers where DOT1L function is implicated, such as multiple myeloma (related coverage). However, EPZ5676 is not a pan-epigenetic modulator; it shows minimal activity against non-DOT1L methyltransferases, and its efficacy is context-dependent, with maximal impact in MLL-fusion positive models.

Common Pitfalls or Misconceptions

• EPZ5676 is not effective in cancers lacking DOT1L-dependency or MLL-rearrangements; off-target effects are minimal but do not confer broad epigenetic modulation.
• The compound is insoluble in water, requiring DMSO or ethanol (with ultrasonic assistance) for preparation; improper solubilization can reduce experimental reproducibility.
• Long-term storage of working solutions at temperatures above -20°C can lead to compound degradation and loss of potency.
• Overinterpretation of DOT1L inhibition in non-leukemic or MLL-wildtype cells may yield misleading results; use appropriate controls.
• EPZ5676 is research-use only and not approved for clinical therapy; animal and cell-based findings may not directly translate to human clinical efficacy.

Workflow Integration & Parameters

EPZ5676 (A4166) from APExBIO should be stored at -20°C in solid form. For solution preparation, dissolve at ≥28.15 mg/mL in DMSO or ≥50.3 mg/mL in ethanol, utilizing ultrasonic assistance for ethanol. Working dilutions should be freshly prepared, and stock solutions stored below -20°C are stable for several months. In biochemical assays, maintain physiological buffer conditions (pH 7.4, 25°C) for optimal activity assessment. For cell-based studies, commonly used concentrations range from 0.5–10 nM, with treatment durations of 4–7 days in proliferation or methylation assays. In vivo, dosing regimens of 35–70 mg/kg/day intravenously for 21 days have shown complete regression of MV4-11 xenograft tumors. QC steps should include monitoring cell viability, H3K79 methylation status, and appropriate negative controls (see strategic workflow guide).

For additional context, see DOT1L inhibitor EPZ-5676 for up-to-date documentation, and note how this article expands on mechanistic selectivity, in vivo efficacy, and detailed workflow integration compared to prior summaries (compare here).

Conclusion & Outlook

EPZ5676 is a validated, potent, and selective DOT1L inhibitor that enables precise interrogation of H3K79 methylation in MLL-rearranged leukemia research. Its exceptional selectivity profile, robust in vitro and in vivo efficacy, and clear workflow parameters make it indispensable for epigenetic and preclinical cancer studies. While translation to clinical settings requires further validation, EPZ5676 remains a gold-standard tool for dissecting epigenetic regulation and supporting the next generation of targeted therapies (Anichini et al. 2022).